What shall we recommend to the practising physician and the cardiologist in a general hospital?

  • D. G. Julian
  • P. G. Hugenholtz
Conference paper


I have been asked to address the question of what we should tell the physicians in practice today, bearing in mind the facilities and drugs which are presently available. This excludes rt-PA and any of the newer strategies. As I see it, we have four options. First, we can tell physicians to do nothing. Secondly, we can advise them to use intravenous streptokinase. Thirdly, we can suggest they use intracoronary streptokinase or fourthly we can suggest intracoronary or intravenous streptokinase plus PTCA.


Acute Myocardial Infarction Dutch Study Practice Today Intravenous Streptokinase Intracoronary Streptokinase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gruppo Italiano per lo Studio della Streptochinasi nell’ Infarcto Miocardio (GISSI) (1986) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet i:397–402Google Scholar
  2. 2.
    Yusuf S, Collins R, Peto R et al (1985) Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, re-infarction and side-effects from 33 randomized controlled trials. Eur Heart J 6:556–583PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • D. G. Julian
    • 1
  • P. G. Hugenholtz
    • 2
  1. 1.Department of CardiologyFreeman HospitalNewcastle upon TyneUK
  2. 2.ThoraxcentrumAkademisch ZiekenhuisRotterdamThe Netherlands

Personalised recommendations